

PHARMACEUTICAL 2023

Wave Life Sciences Ltd. Rank 375 of 446









PHARMACEUTICAL 2023

Wave Life Sciences Ltd. Rank 375 of 446



The relative strengths and weaknesses of Wave Life Sciences Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Wave Life Sciences Ltd. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 13% points. The greatest weakness of Wave Life Sciences Ltd. is the variable Assets, Current, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is -137%, being 180% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	98,537
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	71,521
Liabilities, Non-Current	112,082
Other Assets	30,565
Other Compr. Net Income	-210
Other Expenses	681
Other Liabilities	0
Other Net Income	1,578
Other Revenues	3,649
Property and Equipment	17,284
Research and Development	115,856
Selling, General and Administrative Expense	50,513

Output Variable	Value in 1000 USD
Assets	146,386
Liabilities	183,603
Expenses	167,050
Revenues	3,649
Stockholders Equity	-37,217
Net Income	-161,823
Comprehensive Net Income	-161,928
Economic Capital Ratio	-137%

